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ABSTRACT 
Exaggerated Janus kinase-signal transducer and activator of transcription (JAK-
STAT) signalling is key to the pathogenesis of pro-inflammatory disorders, such as 
rheumatoid arthritis and cardiovascular diseases. Mutational activation of JAKs is 
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also responsible for several haematological malignancies, including 
myeloproliferative neoplasms and acute lymphoblastic leukaemia. Accumulating 
evidence links adenosine 5′-monophosphate (AMP)–activated protein kinase 
(AMPK), an energy sensor and regulator of organismal and cellular metabolism, with 
the suppression of immune and inflammatory processes. Recent studies have shown 
that activation of AMPK can limit JAK-STAT-dependent signalling pathways via 
several mechanisms. These novel findings support AMPK activation as a strategy for 
management of an array of disorders characterised by hyper-activation of the JAK-
STAT pathway. This review discusses the pivotal role of JAK-STAT signalling in a 
range of disorders and how both established clinically used and novel AMPK 
activators might be used to treat these conditions. 
 
Keywords: AMP-activated protein kinase; Janus kinase; rheumatoid arthritis; 
myeloproliferative neoplasms; lymphoma 
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1. INTRODUCTION  
The JAK1-STAT pathway is activated by a range of cytokines, such as interferons, IL-
2, and IL-6, which control survival, proliferation and differentiation in a range of 
                                                            
1JAK, Janus kinase. STAT, signal transducer and activator of transcription. IL, interleukin. RA, rheumatoid arthritis. 
CVD, cardiovascular disease. AMPK, AMP-activated protein kinase. IL-6R, IL-6 receptor. sIL-6Rα, soluble IL-6Rα. 
Tyk2, Tyr kinase 2. MCP-1, monocyte chemoattractant protein 1. ERK1/2, extracellular signal–regulated kinase 
1/2. PI3K, phosphatidylinositol 3-kinase. YAP, YES-associated protein. JH, JAK-homology. SH2, Src homology 2. 
FERM, N-terminal 4.1, ezrin, radixin, moesin. PK, pseudokinase. ALL, acute lymphoblastic leukaemia. MPN, 
myeloproliferative neoplasm. WT, wild type. LKB1, liver kinase B1. AICAR, 5-aminoimidazole-4-carboxamide 
riboside. MKP-1, mitogen-activated protein kinase phosphatase-1. SMCs, smooth muscle cells. mTOR, 
mammalian target of rapamycin. TSC2, tuberous sclerosis complex 2. NOTCH1, notch homolog protein 1. 
CDKN2A/B, cyclin-dependent kinase Inhibitor 2A/B. FBXW7, F-box and WD repeat domain containing 7. PHF6, 
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diverse cell types. Uncontrolled JAK-STAT signalling is not only a crucial driver of 
chronic inflammatory diseases such as rheumatoid arthritis (RA) and cardiovascular 
diseases (CVDs) but also several haematological disorders [1–3]. 
AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that regulates cellular and 
organismal metabolism by sensing increases in the intracellular ratio of AMP to ATP 
following nutrient deficiency or hypoxia [4]. An increasing body of evidence has 
linked AMPK activation with the control of inflammation and immunity via a variety of 
mechanisms [4–6]. This novel finding provides a foundation for the evaluation and 
repurposing of well-tolerated, clinically available drugs, such as the anti-
hyperglycaemic drug and AMPK activator metformin, for the treatment of a range of 
JAK-dependent disorders. Further insights into the novel inhibitory mechanism of 
AMPK might also provide a basis for the development of a new generation of 
selective JAK inhibitors.  
Clinically available drugs can have positive effects beyond their intended targets e.g. 
statins, inhibitors of cholesterol production, also show anti-inflammatory effects which 
are beneficial for the treatment of CVDs [7]. The discovery of novel regulatory 
mechanisms important in disease and the positive secondary effects of existing 
drugs enables drug repurposing and thus expansion of available therapeutic options. 
Given the cost and time required to develop new drugs and test the efficacy and 
safety in clinical trials, re-purposing is advantageous as it increases the speed to 
clinic and availability of drugs while eliminating unknown variables in dosing and 
adverse drug reactions [8,9]. 
This review discusses the pivotal role of JAK-STAT signalling in inflammatory and 
myeloproliferative disorders and provides a molecular rationale for an additional way 
to manage such conditions via repurposing of clinically available AMPK activators. 
 
2. IL-6-DEPENDENT JAK-STAT SIGNALLING 
IL-6 does not signal directly but first forms a dimer with IL-6Rα (CD126) prior to 
binding its cognate receptor gp130.  While gp130 is ubiquitously and constitutively 
                                                            
PHD finger protein 6. ECs, endothelial cells. HUVECs, human umbilical vein ECs. IFN, interferon. IFNAR, IFN/ 
receptor. ULK1, Unc-51–like autophagy-activating kinase. HSCT, haematopoietic stem cell transplant. mAbs, 
monoclonal antibodies. FLT3, FMS-like tyrosine kinase 3. PV, polycythaemia vera. ET, essential 
thrombocythemia. PMF, primary myelofibrosis. ACPA, anti-citrullinated protein antibodies. Th, T helper. Treg, 
regulatory T cell. DMARDS, disease modifying anti-rheumatic drugs. TNF, tumour necrosis factor. GLINT, glucose 
lowering in non-diabetic hyperglycaemia trial. CRLF, cytokine-receptor like factor 2.  
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expressed, membrane bound IL-6R is restricted to hepatocytes, leukocytes, and 
lymphocytes. However, soluble IL-6R (sIL-6R) is produced during inflammation 
thus increasing the repertoire of IL-6-responsive cells [10,11]. Signalling via 
membrane bound IL-6R is called ‘classical signalling’ while that via sIL-6R is 
referred to as ‘trans-signalling’ with the latter being predominant in disease-related 
pro-inflammatory responses. Gp130 has no intrinsic kinase activity but is 
constitutively associated with JAK family tyrosine (Tyr) kinases. JAKs comprise a 
family of four cytoplasmic tyrosine kinases (JAK1-3, and Tyk2). However gp130 only 
associates with JAK1-2 and Tyk2, while type I cytokine receptors for IL-2 and related 
cytokines use the common gamma chain (c) to associate with JAK3 and signal 
downstream [12]. Cytokine-receptor ligation precedes trans-phosphorylation and 
activation of JAKs, which Tyr phosphorylate gp130 on specific Tyr residues to 
generate docking sites for SH2-domain-containing STAT proteins. Receptor-bound 
STATs are then Tyr-phosphorylated by JAKs within their SH2 domains (Tyr701 on 
STAT1, Tyr705 on STAT3) prior to dissociation from the receptor and formation of 
homo- or heterodimers, or tetramers. Following nuclear translocation and binding to 
target gene promoters, STATs drive transcription of target genes, which include pro-
angiogenic vascular endothelial growth factor, intracellular adhesion molecule 1, 
monocyte chemoattractant protein 1 (MCP-1), and matrix metalloproteases 2 and 9 
[12]. IL-6 also activates extracellular signal–regulated kinase (ERK)1/2 and 
phosphatidylinositol 3-kinase (PI3K) pathways following recruitment of SH2-
containing protein Tyr phosphatase 2 to JAK-phosphorylated gp130 and ERK1/2-
mediated phosphorylation and activation of Gab1. Finally, gp130 has also been 
shown to couple directly with Src family Tyr kinases to trigger activation of 
transcriptional co-activator YAP (YES- associated protein) (reviewed in [12]). 
 
3. JAK STRUCTURE AND ACTIVATION 
JAKs share a common domain structure (Figure 1) consisting of seven JAK-
homology (JH) domains (JH1, kinase domain; JH2, pseudokinase domain, JH3-5, 
Src homology 2 (SH2) domain, and JH5-7, N-terminal 4.1, ezrin, radixin, moesin 
(FERM) domain). While FERM and SH2 domains regulate binding to the box1/2 
region of cytokine receptors, the so-called “pseudokinase” (PK) domain regulates 
kinase activity by binding the JH1 kinase domain. Specific events of JAK activation 
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remain unclear, however, cytokine-receptor ligation is thought to cause repositioning 
or reorientation of the JAK-receptor complexes, bringing JAKs into close proximity, 
leading to trans-phosphorylation of the activation loop within the JH1 kinase domain. 
Several distinct mechanisms have been proposed for JAK activation but in addition, 
unique receptor structures are also thought to enforce specific JAK orientations that 
might drive different modes of regulation [13]. This could be one mechanism that 
leads to preferential assembly of specific receptor-JAK complexes, thus fine tuning 
downstream signalling [14]. With such variations, specific targeting of distinct 
receptor-JAK complexes may represent an alternative approach to developing new 
therapeutics targeting this pathway in disease states [13]. 
Activating mutations are frequently found within the regulatory PK domain including 
JAK1V658F and JAK2V617F, which are associated with acute lymphoblastic leukaemia 
(ALL) and myeloproliferative neoplasms (MPNs) respectively. Receptor association 
is essential for sustained JAK activation suggesting the JAK-receptor interaction as a 
possible drug target [15]. Both phenylalanine mutations cause rearrangements within 
a highly conserved Phe-Phe-Val triad [16], leading to rearrangement and stabilisation 
of distinct structures within the PK domain, including the C helix and SH2-PK linker 
regions [17]. Conformational changes break the JH1-JH2 interaction, relieving auto-
inhibition and causing an elevation in catalytic activity [13]. A similar process of 
rearrangement and activation is thought to occur in WT JAKs upon cytokine receptor 
stimulation [16]. The JAK2 PK domain has been shown to have weak catalytic 
activity, allowing inhibitory autophosphorylation of Ser523 and Tyr570 residues which 
stabilises the JH1-JH2 interaction [18]. The JAK2V617F mutation is thought to promote 
JAK2 activation in part by preventing PK catalytic activity [16]. JAK kinase activity is 
further regulated by phosphorylation of Tyr221 which increases activity [19]. 
Interestingly, disrupting PK ATP binding reduces JAK2V617F activity while leaving WT 
JAK2 unaffected [20]. 
In summary, it is now clear that JAKs offer several sites that could be targeted by 
small molecules, including the JH1 and JH2 domains, ATP binding and regulatory 
phosphorylation sites, as well as FERM-SH2/receptor interaction sites. Furthermore, 
variations in receptor-JAK interactions and distinct regulatory modes of individual 
JAK isoforms may enable highly specific targeting of dysfunctional pathways and 
therefore reduce adverse off-target effects. 
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4. CURRENT THERAPEUTIC STRATEGIES TARGETING THE JAK-STAT 
PATHWAY 
Several agents have been developed that target the JAK-STAT pathway at multiple 
levels. In the case of IL-6 signalling, the monoclonal anti-IL-6 antibody siltuximab 
[21], and the humanised anti-IL-6R antibody tocilizumab [22] have been approved for 
clinical use. Anti-IL-6 therapies have been approved for Castleman disease [23], a 
benign lymphoproliferative disorder, and RA [24]. However, single cytokine-targeting 
therapies only partially limit a disease phenotype and become less effective over 
time due to immunogenicity [25]. In other disorders such as multiple myeloma, 
targeting IL-6 alone has only limited benefit, potentially due to reliance on a range of 
other growth factors including IL-6-family cytokines which also signal via the signal 
transducing gp130 receptor. Also, while inhibitors of STATs, which mediate many of 
IL-6’s intracellular effects, have also been developed, they have only shown limited 
effects [26]. As such, current focus has been on the development of JAK inhibitors or 
“Jakinibs”.  
First generation Jakinibs such as tofacitinib (CP-690,550) are pan-JAK inhibitors 
which act as competitive inhibitors of the ATP-binding site in the JH1 domains 
conserved amongst all 4 JAK isoforms (JAK1-3, Tyk2: Figure 1). However, inhibition 
of all JAK isoforms will inhibit the action of multiple cytokines, which when coupled 
with possible off-target effects, can result in unwanted adverse reactions including 
disrupted haematopoiesis, innate and adaptive host defence responses. Future 
development of second generation Jakinibs, which target less conserved regions of 
JAKs, is aimed at producing more selective drugs with less side effects, although 
these may display reduced efficacies versus less selective inhibitors (reviewed by 
Banerjee et al. [25]). It will be beneficial to specifically target mutated JAKs since 
simultaneous inhibition of wild type JAKs can have negative effects. A recent finding 
that disrupting JAK PK domain ATP binding reduces JAK2V617F activity leaving WT 
JAK2 unaffected has led to the identification of PK domain small molecule binders 
which might lead to the development of a range of novel JAK inhibitors [27]. 
Research in Jakinib development is progressing with a number of drugs entering 
clinical trials [26]. However, there is still a need for therapeutics that are efficacious 
but with minimal side effects. The discovery of unappreciated targets of clinically-
available drugs and important regulatory cellular molecules has accelerated drug 
repurposing efforts. Repurposing offers the possibility of speedy transition through 
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clinical trials with the advantages of having known tolerable dosages and 
manageable side effects. Here, we discuss current understanding of AMPK and the 
possibilities of repurposing AMPK activators for the treatment of inflammatory and 
myeloproliferative disorders. 
 
5. AMP-ACTIVATED PROTEIN KINASE (AMPK) 
AMPK activation following cellular stress, such as nutrient deficiency and hypoxia, 
triggers a switch in metabolism from ATP consumption to ATP generation in order to 
maintain energy homeostasis. AMPK is a heterotrimeric complex consisting of a 
catalytic  subunit and regulatory  and  subunits. In mammals, seven genes 
encode two  (1-2), two  (1-2), and three  (1-3) subunit isoforms. The subunits 
of the 111 complex are ubiquitously expressed and most intensively studied. 
Other subunit isoforms show tissue specific expression patterns, while variations in 
subcellular location have also been reported [28–31]. It is likely that tissue specific 
expression of distinct subunit isoforms will be important for therapeutically targeting 
specific disorders through AMPK activation [32–34].  
AMPK is activated by allosteric binding of AMP/ADP to the  regulatory subunit and 
Thr172 phosphorylation of catalytic 1 and 2 subunits by the upstream Ser/Thr 
Kinase liver kinase B1 (LKB1). Binding of AMP also inhibits Thr172 de-
phosphorylation by protein phosphatase PP2A. However, AMPK can also be 
activated by Thr172 phosphorylation alone independent of changes in cellular ATP 
and AMP levels via calcium/calmodulin-dependent protein kinase kinase  following 
elevation of intracellular Ca2+ levels. Phosphorylation of the catalytic α subunit and 
thus full AMPK activation is also dependent on N-terminal myristoylation of the  
subunit, which interacts with both  and  subunits [35]. 
Several direct and indirect activators of AMPK (reviewed by Kim et al [36]) have been 
identified, including aminoimidazole-4-carboxamide riboside (AICAR), metformin, 
salicylate, and A769662. AICAR is metabolised to AICAR monophosphate (ZMP) 
which directly activates AMPK by mimicking AMP-dependent activation by binding  
subunits. A769662 is selective for 1 subunit-containing complexes and similar to 
AMP, allosterically activates and inhibits Thr172 de-phosphorylation, however, it 
employs a different mechanism in which Thr172 phosphorylation is not required 
[37,38]. Aspirin, the pro-drug of salicylate, is structurally similar to A769662 and 
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activates 1 subunit-containing complexes in a similar manner, although salicylate 
binds at an overlapping allosteric binding site and can thus antagonise activation by 
A769662 [39]. Metformin, a clinically available anti-hyperglycaemic drug used to 
manage type 2 diabetes mellitus (T2DM), indirectly activates AMPK by depleting 
ATP via inhibition of complex I of the mitochondrial respiratory chain [40], and 
mitochondrial glycerophosphate dehydrogenase [41] as well as an Axin-dependent 
lysosomal pathway [42]. However, many AMPK activators lack specificity and 
therefore it is necessary to differentiate between their AMPK-dependent and -
independent effects  [37,38,43–45]. 
 
6. AMPK LINKS METABOLISM AND INFLAMMATION 
AMPK is a crucial regulator of energy metabolism, however its anti-inflammatory 
effects have been reported in several human cell types and multiple animal models 
of disease [46–49]. For example, prolonged STAT1 activation leads to accelerated 
neo-intimal formation and atherosclerosis while AMPK2 knockout mice have an 
enhanced STAT1-dependent inflammatory response. Pharmacological or genetic 
activation of AMPK, or treatment with the STAT1 inhibitor fludarabine reversed the 
response suggesting that AMPK is potentially protective against vascular 
inflammation and atherosclerosis [50]. The available literature suggests that AMPK 
inhibits multiple signalling pathways to mediate its anti-inflammatory effects [4]; these 
include inhibition of NF-B signalling [51–53] and multiple mitogen-activated protein 
kinase pathways [54], and reducing reactive oxygen species production [54]. 
Other groups, including our own, have reported AMPK-dependent inhibition of JAK-
STAT signalling [49,50,55–57]. Potential mechanisms for the observed AMPK-
mediated suppression of IL-6 responses include the induction of orphan nuclear 
receptor small heterodimer partner (SHP) [57]. Long-term metformin treatment of 
primary rat hepatocytes was found to trigger an AMPK-dependent accumulation of 
SHP, which co-localised with STAT3 in the nucleus to reduce DNA binding and 
inhibit expression of pro-inflammatory genes including suppressor of cytokine 
signalling 3, serum amyloid A, IL-6, and tumour necrosis factor (TNF) α [57]. In 
contrast, others have shown in HepG2 human hepatoma cells that chronic AICAR-
mediated AMPK activation inhibits IL-6 signalling by suppressing JAK1/JAK2 tyrosine 
phosphorylation and activation, although the mechanism responsible was not 
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investigated [49,55].  In addition, AMPK-dependent induction of mitogen-activated 
protein kinase phosphatase-1 (MKP-1), a Thr/Tyr dual specificity protein 
phosphatase, has been proposed to inhibit STAT1 activation in human aortic smooth 
muscle cells (SMCs) [50]. MKP-1 has previously been reported to specifically target 
Ang-II-activated STAT1 whilst leaving STAT3 unaffected [58,59]. AMPK also reduced 
Ang-II induction of STAT1 target genes including MCP-1 in addition to STAT1-
dependent vascular inflammation in vivo. Another mechanism by which AMPK could 
potentially inhibit JAK-STAT signalling is through its well-characterised suppression 
of the mammalian target of rapamycin (mTOR) pathway through direct 
phosphorylation and inhibition of Raptor and activation of the Rheb GTPase-
activating protein tuberous sclerosis complex 2 (TSC2) [60,61]. However despite 
reports demonstrating that inhibition of mTOR signalling suppresses JAK-STAT 
activation [62,63], the molecular mechanisms responsible for this phenomenon 
remain unknown. 
Using human umbilical vein ECs (HUVECs) as a model system, we showed that a 
panel of AMPK activators, including A769662, AICAR and a combination of 
metformin with salicylate, rapidly inhibited STAT3 activation by a sIL-6Rα/IL-6 trans-
signalling complex [64]. We have reported a similar rapid inhibition of sIL-6Rα/IL-6-
stimulated STAT3 phosphorylation by A769662 in 3T3-L1 adipocytes [65]. We also 
demonstrated that the inhibitory effect of AMPK by A769662 was observed on both 
STAT1 and STAT3 phosphorylation in response to oncostatin M and leukaemia 
inhibitory factor, both of which also utilise gp130 to signal downstream [64]. 
Importantly, the effect of AMPK was not restricted to cytokines utilising gp130, as 
STAT1 phosphorylation in response to interferon  (IFN) was also inhibited, 
suggesting that AMPK was acting at a common post-receptor locus to mediate its 
effects [64]. JAK1 is immediately downstream of both gp130 and the IFN receptor 
(IFNAR)1/IFNAR2 complex responsible for IFN signalling, and activation of AMPK 
resulted in a phosphorylation of JAK1 on Ser515 and/or Ser518 responsible for rapid 
inhibition of JAK-STAT signalling [64]. Importantly, AMPK was also able to inhibit 
constitutive signalling from oncogenic JAK1V658F prevalent in ALL [64]. In terms of the 
mechanism, AMPK-mediated JAK1 phosphorylation on Ser515 and/or Ser518 
supresses downstream signalling either directly or indirectly by promoting binding to 
14-3-3 proteins, which regulate target protein function by disrupting protein-protein 
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interactions that induce changes in activity or subcellular localisation [66]. Several 
AMPK substrates, including B-Raf, Unc-51–like autophagy-activating kinase (ULK1) 
and Raptor, have been shown to bind 14-3-3 proteins following AMPK-dependent 
phosphorylation [60,67,68]. We have identified JAK1 as a similarly regulated AMPK 
substrate since pharmacological activation of AMPK promoted 14-3-3 binding to 
JAK1 via a mechanism requiring phosphorylation of Ser515 and Ser518  [64]. However 
the functional importance of 14-3-3/JAK1 interaction in intact cells remains to be 
tested. 
In summary, the existence of several inhibitory mechanisms by which AMPK can 
suppress JAK-STAT signalling mirrors the multifaceted impact of AMPK on the 
mTOR signalling pathway, which it inhibits through direct phosphorylation of TSC2 on 
Ser1387 and Raptor on Ser722 and Ser792 [60,61,69] (Figure 2A). These observations 
suggest that, like the mTOR pathway, AMPK-mediated regulation of JAK-STAT 
signalling has also evolved such that multiple mechanisms and targets are used to 
limit its activation. 
 
7. REPURPOSING OF AMPK ACTIVATORS  
AMPK is a critical global regulator of stress including nutrient deficiency, hypoxia, 
and inflammation. This provides a strong rationale for both the development of novel 
AMPK agonists and the repurposing of those already used in the clinic. Here we 
provide a molecular rationale to support the application of AMPK activation as a 
therapeutic strategy for management of conditions resulting from hyperactivation of 
the JAK-STAT pathway, such as ALL, MPNs and RA. 
7.1 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) 
ALL is an aggressive haematological malignancy affecting all age groups but 
primarily associated with young children, making it a particularly distressing disease. 
ALL is the most common paediatric cancer, accounting for 26% of all cancer cases in 
children [70]. While ALL can occur in adults, the patients age and ethnicity are 
important factors for prognosis; male, Hispanic children statistically have the most 
aggressive forms of ALL [70].  
ALL is characterised by the accumulation of lymphoblasts arrested at specific stages 
of differentiation caused by the transformation of B/T cell progenitors. Initiating 
mutations in regulators of differentiation are subsequently perpetuated by activating 
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and inactivating mutations in pathways that drive proliferation/survival and tumour 
suppression respectively [71].  Classified into B-cell ALL (B-ALL), T-cell ALL (T-ALL), 
and Natural Killer ALL (NK-ALL), T-ALL is the more clinically aggressive. However, 
T-ALL is less common accounting for approximately 15% of paediatric ALL cases, 
NK-ALL is rare at 3% while the rest consists of B-ALL [70,72,73]. ALL classes are 
each split into primary genetic subtypes: for T-ALL, these are defined by mutations in 
signalling protein neurogenic locus notch homolog protein 1 (NOTCH1), cell cycle 
regulator cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B), E3 ubiquitin ligase 
component F-box and WD repeat domain containing 7 (FBXW7) and PHD finger 
protein 6 (PHF6), which has no known function [74]. Further secondary genetic 
mutations are also common such as those within the JAK-STAT pathway. Multiple 
activating mutations of JAKs, such as the constitutively active JAK1V658F and 
JAK2V617F which drive cell proliferation and survival [70], are associated with ALL 
while enhanced activation of JAK-STAT signalling is detected in 3-10% of all patients 
with all T-cell malignancies (reviewed by Waldmann and Chen [75]). Therefore at 
least some of these patients may benefit from therapeutic approaches that limit JAK-
STAT signalling. 
Chemotherapy is the first line treatment for ALL, involving delivery of an intensive 
combination of cytotoxic compounds. However, treatment often induces long-term 
adverse effects which either impair vital physiological functions or induce further 
complications, including secondary tumours and pulmonary and cardiovascular 
disorders [70,76]. 20-25% of children with T-ALL experience relapse and are often 
resistant to further chemotherapy; the outcome at this point being much worse [77]. 
Survival rates in paediatric ALL have improved dramatically in the last 50 years 
(currently 85–90%) following advances in genetic subtyping and personalised 
treatment regimens [78,79]. Allogeneic haematopoietic stem cell transplant (HSCT) 
therapy has been used to treat high risk patients following relapse. However, HSCT 
is associated with high risks of treatment failure and treatment-related mortality 
[70,80]. High risk patients are often treated with local or whole body radiotherapy 
which require antibiotics to prevent infection while other complications such as 
anaemia and risk of bleeding are treated with blood transfusions and platelet 
transfusions respectively [73]. 
Additional therapies are being developed with varying degrees of success [81,82]. 
These include targeting cell surface receptors overexpressed on T/B cells using 
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monoclonal antibodies (mAbs). Several cell surface antigens are common to  
precursor B-ALL (CD10, CD19, CD34) and T-ALL (CD2, CD3, CD7) cells [73]. 
Monoclonal antibodies are currently available which target CD20 specifically 
(rituximab) and both CD3 and CD19 simultaneously (the bispecific antibody 
blinatumomab) to induce complement activation, antibody-dependent cellular 
cytotoxicity and apoptosis [82]. Tyrosine kinases which drive survival and 
proliferation, such as BCR-ABL and FMS-like tyrosine kinase 3 (FLT3), are 
frequently overexpressed in leukaemic cells and have been targeted with tyrosine 
kinase inhibitors [70]. Multiple clinical trials are ongoing to investigate other novel 
agents including the use inhibitors towards the 26S proteasome, histone 
deacetylases [83], DNA methyltransferases [84], mTOR [85] and others [81,82] for 
use as either single or combination therapies. 
It is apparent that new strategies are required which overcome the long-term side 
effects, relapse, and resistance associated with chemotherapies. One option is to 
specifically target aberrantly activated signalling pathways which drive proliferation 
and survival of cells. Aberrant JAK-STAT signalling is implicated in ALL pathogenesis 
[75]. Targeting the JAK-STAT pathway has shown positive effects on the disease 
phenotype [86] while activating mutations of JAK1 are frequently associated with 
cases of ALL [87–90]. The JAK1V658F mutation identified in T-ALL patients [90–92] 
drives the ligand-independent activation of STATs [93,94] and its expression can 
induce transformation of Ba/F3 pro-B cells [87,89,95]. Subtypes of leukaemia have 
also been reported with hyperactive JAK-STAT signalling in the absence of activating 
mutations [86]. As such, both WT and constitutively activate JAK mutants are an 
attractive therapeutic target for treating ALL. 
We have demonstrated that AMPK can block JAK-STAT signalling via inhibition of 
WT and constitutively active JAK1V658F via a mechanism that requires JAK1 
phosphorylation on Ser515/518 [64]. Thus inhibition of JAK-dependent ALL via AMPK 
activators might have positive effects on haemostasis. Furthermore, inhibiting JAK-
STAT signalling might limit secondary side effects produced following current 
treatments regimens such as cardiovascular and pulmonary disorders. Therefore, 
this provides a basis for the evaluation and repurposing of clinically utilised AMP-
activating drugs, such as metformin and thiazolidinediones, as potential treatment 
options for ALL associated with constitutive JAK1 signalling. In support of this, 
metformin has previously been investigated as a candidate to target T-ALL through 
13 
 
AMPK-mediated inhibition of the PI3K/mTOR pathway, which is hyper-activated in 
approximately 85% of T-ALL cases [96]. Grimaldi et al. demonstrated that metformin-
activated AMPK inhibited mTOR and induced apoptotic cell death [96–99]. Thus 
AMPK activators might be effective in treating both JAK-STAT and PI3K/mTOR-
dependent aspects of T-ALL cell dysfunction. To examine this, a clinical trial is 
currently on-going investigating the treatment of relapsed ALL with a combination of 
metformin and chemotherapy [96] (trial identifier:NCT01324180). 
 
7.2 MYELOPROLIFERATIVE NEOPLASMS (MPNS) 
Myeloproliferative neoplasms are a group of three haematological malignancies, 
termed polycythaemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF), which are characterised by uncontrolled proliferation of 
CD34+CD38- haematopoietic stem/progenitor cells. An acquired JAK2V617F mutation 
analogous to T-ALL-associated JAK1V658F results in unregulated cytokine-
independent JAK2 activation and is frequently detected in PV (>95% of cases), ET 
(∼50%), and PMF (∼50%) [100–102]. 
Thrombohaemorrhagic events and disease transformation into acute myeloid 
leukaemia (AML) are complications and main causes of morbidity and mortality in PV 
and ET [103]. It is not known how these complications arise and current treatments 
are limited to phlebotomy (PV patients only), low dose aspirin anti-platelet therapy (to 
reduce risk of thrombosis), and cytoreduction with hydroxyurea, anagrelide, IFNα, 
and alkylating agents such as busulfan [104]. A subpopulation of MPN patients have 
been found to express JAK2V617F in endothelial cells suggesting a further cellular 
target for MPN therapies [105]. Moreover, Etheridge et al. [106] found that mice 
engineered to express JAK2V617F in either ECs, haematopoietic cells or both cellular 
compartments developed an MPN phenotype with attenuated thrombosis following 
injury. It is thought that JAK2V617F contributes to the bleeding phenotype in part via 
the inhibition of function or secretion of the pro-thrombotic molecule von Willebrand 
factor, and reduced levels of agglutination. Together, these data suggest that 
targeting JAK-STAT signalling in both cellular compartments might be effective for 
the treatment of JAK2V617F-positive MPNs. Ruxolitinib, a dual JAK1/2 inhibitor, is 
approved for the treatment of intermediate/high-risk PMF and successful clinical trials 
have been carried out on JAK2V617F-positive individuals who were unresponsive to 
other treatments [104]. However, reductions in disease phenotype were frequently 
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accompanied by haematological side effects such as thrombocytopenia and anaemia 
as well as other non-haematological events including diarrhoea and pyrexia. 
Kawashima and Kirito [103] have reported that metformin treatment of JAK2V617F-
positive MPN cell lines induced AMPK activation, leading to decreased levels of 
STAT5 phosphorylation and induction of apoptotic cell death. Furthermore, alignment 
of the primary sequences of JAK family members (Figure 2B) reveals conservation of 
the SH2 domain–localised AMPK phosphorylation sites we identified on JAK1 [107]. 
Together, these findings suggest that AMPK might also inhibit a range of 
constitutively active JAK mutants including JAK2V617F. As such, AMPK activators 
might also be beneficial in the treatment of JAK2V617F-associated MPNs via the 
management of both anti-proliferative effects and haemostatic defects. 
 
7.3 RHEUMATOID ARTHRITIS (RA) 
Rheumatoid arthritis is a common autoimmune disease characterised by synovial 
inflammation and hyperplasia, autoantibody production and destruction of cartilage 
and bone. It is also accompanied by systemic features including cardiovascular, 
pulmonary, psychological, and skeletal disorders [108]. Although the aetiology of RA 
is not fully understood, recent evidence suggests that autoimmune responses to 
citrullinated epitopes predominantly present on matrix proteins plays a central role in 
pathology [109]. Anti-citrullinated protein antibodies (ACPAs) are a measure of B-cell 
activation [110,111] and elevated ACPA levels are a biomarker for aggressive RA 
[112]. Acute phase proteins such as IL-6 also play a crucial role in RA pathogenesis 
and elevated levels of IL-6 in serum and synovial fluid are markers of the disease 
[113]. IL-6 initiates and sustains inflammation and degeneration by inducing the 
acute-phase response, directly activating B and T lymphocytes, macrophages and 
osteoclasts, and promoting infiltration of inflammatory cells, and production of matrix 
metalloproteinases [113]. 
IL-6-activated CD4+ T-cells, key drivers of RA, differentiate to specific T helper (Th) 
lymphocytes which drive distinct immune responses. Th1 cells secrete IFN, IL-2, 
and TNF) , which activate macrophages to enhance cell-mediated immunity and 
phagocytic responses, whereas Th2 cells generate IL-4, IL-5, IL-10, and IL-13 to 
stimulate B-cell-mediated antibody production and activate eosinophils. A recently 
identified CD4+ T-cell lineage, Th17 cells, secrete cytokines such as IL-17 and IL-21 
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which activate JAK-STAT signalling in multiple cell types. This stimulates the 
secretion of chemokines, cytokines, and colony-stimulating factors which activate 
and recruit neutrophils and other myeloid cells leading to an exacerbated 
inflammatory response [114]. Th17 cells are less understood, in part because their 
pattern of differentiation in humans is distinct from that of mouse. However STAT3-
dependent transcription is thought to be a common crucial factor in both systems 
[114]. IL-6 stimulates the differentiation of pathogenic Th17 cells from naive T-cells 
but is not required for Th17 maintenance following differentiation [115]. Furthermore, 
IL-6 inhibits the TGF-β-induced development of immunosuppressive regulatory T 
cells (Treg) [116–118]. Therefore, upon sustained, elevated levels of IL-6, the fine 
balance between Th17 cells and Tregs is lost, thereby promoting an enhanced 
immune response [116–118]. IL-6 can also inhibit the differentiation of Th2 cells [119] 
while also promoting the differentiation of immature B-cells into antibody-secreting 
cells [120]. The latter is thought to be an indirect response of IL-6 stimulating the B 
cell helper capabilities of CD4+ T cells through increased IL-21 production [120]. 
Thus, an increase in Th1 and Th17 cells and a decrease in Th2 and Treg T-cells 
promotes a pro-inflammatory, macrophage-dependent response. In an incompletely 
understood process, escalating levels of pro-inflammatory cytokines secreted by 
numerous cell types cause a vicious feedback cycle leading to local and systemic 
pathogenesis. 
As a major driver of RA-dependent events, IL-6-dependent JAK-STAT signalling has 
been intensively studied and its components are targets for therapeutic intervention 
by small molecule inhibitors and biologicals [121,122]. 
 
7.3.1 TARGETING RA BY INHIBITING IL-6-JAK-STAT SIGNALLING  
RA is commonly treated using conventional disease modifying anti-rheumatic drugs 
(DMARDs) (ciclosporin, sulfasalazine, and methotrexate), slow-acting drugs that 
reduce disease progression. There is an on-going development of novel biologics 
that specifically target the cause of inflammation including anti-TNF (infliximab, 
adalimumab, certolizumab and golimumab) [123], co-stimulatory receptors 
CD80/CD86:CD28 required for full T-cell activation (abatacept), anti-CD20 which 
targets B cells (rituximab), and anti-IL-6R (tocilizumab)[124].  
Tocilizumab, a humanised anti-IL-6R antibody which binds and inhibits both IL-6R 
and sIL-6Rα, has been used successfully for treatment of RA [116–118]. While the 
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previously mentioned biologics are often combined with methotrexate to increase 
efficacy, no additive effect is seen with tocilizumab and methotrexate suggesting 
targeting of the same pathway [124]. This finding is supported by Thomas et al. [125] 
who demonstrated that, in addition to several possible mechanisms of action [126], 
methotrexate also targets JAKs. It is therefore possible that, while improving RA 
prognosis, IL-6/JAK-directed mono-therapy might also have fewer side-effects. 
Most recently, tofacitinib, a ATP-competitive JAK1/3 inhibitor, was approved by the 
US FDA for RA treatment of patients who are intolerant/resistant to first line therapies 
such as methotrexate (reviewed by Nakayamada et al. [127]). A small number of 
studies have demonstrated that AMPK activators, metformin and A769662, 
suppressed inflammatory arthritis in murine models of RA [128,129]. It has also been 
reported that AMPKα1-deficient mice exhibit a mildly enhanced inflammatory arthritis 
versus wild type controls [130]. Moreover, Kang et al. reported that metformin inhibits 
Th17-cell differentiation both in vivo and ex vivo, and AMPK activation inhibits STAT3 
phosphorylation in CD4+ T cells in vitro [129]. Together with our own data, this 
suggests that metformin might suppress Th17 cell differentiation by inhibiting STAT3 
phosphorylation in part via AMPK-mediated phosphorylation of JAK1. 
 
8. SUMMARY AND PERSPECTIVES 
This review has evaluated data which provides a mechanistic rationale for 
repurposing clinically available drugs for the targeted activation of AMPK to treat an 
array of JAK-dependent disorders. An increasing body of evidence has shown that 
changes in cellular nutritional status impact on immune and inflammatory status via 
AMPK [131]. Upon stress, AMPK activation acts to limit JAK-STAT-dependent pro-
inflammatory signalling via several mechanisms to initiate a protective response. 
JAK-STAT signalling is crucial in the development of several pro-inflammatory 
disorders such as rheumatoid arthritis, cardiovascular disease, as well as 
myeloproliferative neoplasms such as acute lymphoblastic leukaemia. Novel findings 
suggest that AMPK can limits JAK-STAT signalling driven by constitutively active 
JAK1V658F and, based on sequence similarity between JAK isoforms (Figure 2B), the 
same mechanism may inhibit other constitutively active JAKs associated with 
disease [107]. Such mutations are common in haematological malignancies for which 
current treatments are either limited or harmful. Therefore, repositioning current 
medications or developing novel small molecule AMPK activators or biologics, used 
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alone or in a combined regimen, might provide a more efficacious but less harmful 
therapy.  
Repositioning of drugs is the reuse of existing pharmaceutical agents to alleviate 
symptoms unconnected with the primary disorder. Successful repositioning of 
existing drugs has been documented over the decades [9], although it is not without 
its own drawbacks [8]. Given the cost/time of research and development and clinical 
trials with new drugs, re-purposing is advantageous as it increases the speed to 
clinic and availability of drugs while eliminating unknown variables such as tolerable 
dosages and side-effects. There is potential for current therapeutics for arthritis and 
proliferative diseases i.e. tocilizumab, tofacitinib and ruxolitinib, which target IL-6-
dependent JAK-STAT signalling, in the treatment of vascular disease [132]. While 
approved for RA, tofacitinib is also being investigated for use against other 
autoimmune diseases [133]. Moreover, statins, which inhibit cholesterol production 
and are widely prescribed for management of cardiovascular disease, have shown to 
target IL-6-dependent disorders by limiting STAT3 activation through blocking IL-6 
production [134,135]. Activation of AMPK by clinically available drugs including the 
anti-hyperglycaemic drug metformin and salicylate, the active metabolite of aspirin 
[136,137], have been shown to have protective effects in the vasculature [138]. We 
have shown that metformin, salicylate, and A769662 can each limit IL-6-dependent 
STAT3 phosphorylation in HUVECs. AMPK was found to directly phosphorylate 
Ser515 and Ser518 within the SH2 domain of JAK1 [64]. AMPK-mediated inhibition of 
JAK-STAT signalling was attenuated upon either mutation of Ser515 and Ser518 
residues or knockdown of AMPK1 catalytic subunits. Together these data support 
AMPK-dependent regulation of JAK signalling as a mechanism that could be further 
investigated with a view to the repurposing AMPK activators for a range of immune 
and inflammatory diseases.  
The AMPK activator metformin is a widely used, relatively safe and inexpensive anti-
diabetic drug and therefore might be beneficial for long-term treatment regimens. 
Common adverse effects of metformin are relatively mild and include hypoglycaemia 
and gastrointestinal intolerance, which can occur in up to 30% of patients. A more 
serious but rare adverse effect is lactic acidosis due to drug overdose or 
administration in contraindicated conditions [139]. It is possible that AMPK-
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dependent inhibition of JAK-STAT signalling might limit secondary side effects of 
current treatments i.e. chemotherapy, such as cardiovascular and pulmonary 
disorders. Several observational studies have reported that treatment with metformin 
limits cardiovascular morbidity and mortality independent from its glucose-lowering 
action in patients with T2DM [140–143]. However, clinical studies showed little or no 
effect on several surrogate markers of cardiovascular disease in non-diabetic 
patients with high cardiovascular risk, taking statins [144], or during cardiac surgery 
[145].  As such, clinical trials of metformin monotherapy are necessary to evaluate 
the cardiovascular protective effects of metformin treatment in non-diabetic patients 
with CVD. One such study is currently ongoing is the Glucose Lowering In Non-
diabetic hyperglycaemia Trial (GLINT; ISRCTN34875079). Over 12 000 patients with 
high cardiovascular risk and abnormal blood glucose levels but without diabetes, will 
be assigned to metformin or placebo for 5 years with data cut-off in December 2024.  
Aspirin  is an acetylated prodrug which is rapidly broken down to the allosteric AMPK 
activator salicylate within the bloodstream [146] and is a well-established anti-platelet 
drug for secondary prevention in patients at high risk of cardiovascular events [147]. 
However, aspirin may adversely impact on haemostasis and cause complications in 
patients prone to bleeding. While low dose aspirin is used to reduce risk of 
thrombosis, myocardial infarction and stroke, it can also cause gastrointestinal 
ulcerations and bleeding [148]. Additionally, further work is necessary to dissect 
AMPK-dependent and -independent effects of current AMPK activators, which lack 
specificity [37,38,43–45]. 
While a pipeline of novel agents is being developed to complement and replace 
existing chemotherapy regimens, the accumulation of genetic changes rapidly results 
in the generation of unresponsive sub-clones of primary tumours. This requires the 
development of a variety of personalised combination therapeutic regimens and as 
such, there is an on-going need to expand the arsenal of anti-cancer agents. For 
example, genetic background will be an important factor which determines the use of 
JAK inhibitions and/or treatment regime either at diagnosis or relapse. A recent 
finding suggested that loss of USP9X, a deubiquitinase and activator of JAK-STAT 
signalling, in cytokine-receptor like factor 2-positive (CRLFpos) ALL might contribute to 
cell survival by limiting JAK signalling [149]. Importantly the same group found that 
low-dose ruxolitinib also had the same effect in USP9X knockout 018z cells 
expressing CRLF2/JAK2R683G. Therefore, it is critical to assess disease status and 
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evolution prior to stratification of patients to the most appropriate therapeutic 
regimen. 
AMPK functions as a heterotrimeric complex of consisting of single α, β, and γ, 
subunits with the α1β1γ1 complex being ubiquitously expressed and most studied. 
Other subunits show tissue specific expression patterns while variations in 
subcellular location have also been reported [28–31]. Therefore expression profiles 
and functions of specific AMPK isoform complexes might be exploited to design 
AMPK activators which target defined tissues such as the vasculature. This is 
supported by the identification of several isoform specific direct activators of AMPK 
[45] including salicylate and A769662, which selectively target β1-containing AMPK 
complexes. Furthermore, lymphocytes have been reported to express AMPKα1 
catalytic subunits exclusively, thus fewer heterotrimeric complexes are possible 
which might allow specific targeting of diseases such as ALL [150]. Despite 
numerous reports suggesting that AMPK activators may be beneficial for the 
treatment of cardiovascular disease and a number of human pathologies 
[47,50,130,138] no direct AMPK activators have yet reached clinical use. However, 
two newly developed direct allosteric AMPK activators, PF-739 [151] and MK-8722 
[152], have shown efficacy in improving glycaemic control in primates and may 
therefore prove useful in patients with specific indications. 
The novel finding the AMPK targets JAK1 [107] suggests the possible development 
of AMPK-targeting molecules with enhanced specificity to target JAK1/2-dependent 
tissue specific disorders. JAK inhibitors, such as ruxolitinib and tofacitinib, 
competitively inhibit the JH1 domain ATP-binding site. Structural similarities between 
JAK isoforms in this region means that development of specific JAK inhibitors 
targeting this site is challenging, thus requiring a more novel approach [153] such as 
the not yet exploited approach of targeting the cytokine receptor-JAK interaction. 
Recent advances in JAK structural studies have found that the SH2 domain interacts 
with the cytokine receptor box 2 motif [18,154]. We have shown that AMPK 
phosphorylates JAK1 at Ser518 and Ser515 which are positioned directly beside this 
interaction suggesting this modification disrupts the cytokine receptor-JAK1 SH2 
interaction and downstream signalling. Thus targeting this interaction might allow for 
the design of small-molecule inhibitors with specificity towards distinct JAK isoforms 
and JAK-receptor combinations.  
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Together, current data suggests that targeting AMPK with clinic-ready drugs and 
exploiting its novel regulatory mechanisms might usher in a new generation of 
selective therapeutics for chronic inflammatory disorders and a range of 
haematological malignancies. 
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FIGURES 
 
 
Figure 1: Human JAK1 and JAK2 domain structure and disease-associated 
mutations resulting in constitutive kinase activation. 
Upper: Schematic diagram of human JAK1 and JAK2 showing the common structure 
conserved in all four JAK isoforms consisting of seven JAK-homology (JH) domains 
(JH1, Tyr kinase domain; JH2, pseudokinase domain; JH3-5, Src homology 2 (SH2) 
domain; JH5-7, N-terminal 4.1, Ezrin, Radixin, Moesin (FERM) domain). While the 
FERM and SH2 domains regulate receptor binding, the pseudokinase domain, which 
has weak catalytic activity [18], regulates JH1 domain Tyr kinase activity. The 
locations of activating mutations in JAK1 detectable in patients with ALL and 
activating mutations in JAK2 observed in MPN patients are indicated. JAK1V658F and 
JAK2V617F mutations within the regulatory JH2 domains are the most frequently 
detected JAK mutations in ALL and MPN respectively [75]. 
Lower: Crystal structure of the JAK2 JH1 domain bound to JAK inhibitor tofacitinib, 
reproduced with permission [155]. 
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Figure 2: Control of the JAK-STAT pathway at multiple levels by AMPK 
Panel A: Schematic representation of the molecular mechanisms by which AMPK 
has been proposed to inhibit JAK-STAT signalling. 1- inhibition of mTOR via Raptor 
inhibition and TCS2 activation. 2- Ser phosphorylation of JAK and downstream 
binding of 14-3-3. 3- dephosphorylation of STAT by MKP-1. 4- increased SHP 
accumulation and prevention of STAT DNA binding and transcription. 
Panel B: Upper - Alignment of SH2 domain regions from the four human JAK 
isoforms. The lettering above the alignment indicates secondary structural elements. 
The residues corresponding to Ser515 and Ser518 in JAK1 are underlined and in bold, 
and the conserved Ser residues in JAK2, JAK3, and Tyk2 equivalent to Ser518 are in 
bold and marked with an asterisk. Box highlights the sequence surrounding the 
conserved Ser residue in each JAK isoform and is colour-coded to show conformity 
to the AMPK phosphorylation consensus sequences indicated below [60]. Lower - 
Structure of the human JAK1 FERM-SH2 fusion (Protein Data Bank: 5IXD) [154]. 
Zoom: Location of Ser518 within the B helix immediately downstream of the EF loop 
in the SH2 domain. The A and B loops present in all SH2 domains are also 
indicated. Figure adapted from Rutherford et al. [64]. 
